Invention Grant
- Patent Title: Compounds for enzyme inhibition
-
Application No.: US14038626Application Date: 2013-09-26
-
Publication No.: US09205126B2Publication Date: 2015-12-08
- Inventor: Han-jie Zhou , Congcong M. Sun , Kevin D. Shenk , Guy J. Laidig
- Applicant: Onyx Therapeutics, Inc.
- Applicant Address: US CA South San Francisco
- Assignee: Onyx Therapeutics, Inc.
- Current Assignee: Onyx Therapeutics, Inc.
- Current Assignee Address: US CA South San Francisco
- Agency: Marshall, Gerstein & Borun LLP
- Main IPC: A61K38/06
- IPC: A61K38/06 ; A61K31/425 ; A61K31/56 ; A61K31/535 ; A61K31/42 ; A61K31/415 ; A61K31/38 ; A61K31/69 ; A61K38/55 ; C07K5/062 ; C07K5/065 ; C07K5/078 ; C07K5/083 ; C07K5/087 ; C07K5/097 ; C07K5/117 ; A61K45/06 ; A61K38/00

Abstract:
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles.
Public/Granted literature
- US20140050737A1 COMPOUNDS FOR ENZYME INHIBITION Public/Granted day:2014-02-20
Information query
IPC分类: